TRAIL, Fas Ligand, TNF and TLR3 in Cancer
This volume provides the current understanding of death receptor's/TLR3 signaling regulation in cancer. Death receptors, including TRAIL-R1, TRAIL-R2, Fas and TNF-RI, owing to their ability to trigger apoptosis and to contribute to the elimination of cancer cells by the immune system have been...
| Συγγραφή απο Οργανισμό/Αρχή: | |
|---|---|
| Άλλοι συγγραφείς: | |
| Μορφή: | Ηλεκτρονική πηγή Ηλ. βιβλίο |
| Γλώσσα: | English |
| Έκδοση: |
Cham :
Springer International Publishing : Imprint: Springer,
2017.
|
| Σειρά: | Resistance to Targeted Anti-Cancer Therapeutics,
12 |
| Θέματα: | |
| Διαθέσιμο Online: | Full Text via HEAL-Link |
Πίνακας περιεχομένων:
- Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer
- TRAIL-R3/R4 and Inhibition of TRAIL Signalling in Cancer
- IAPs and Resistance to Death Receptors in Cancer
- Bcl-2 Proteins and TRAIL Resistance in Melanoma
- Regulation of Caspase-Mediated Apoptosis by the Tumor Suppressor Par-4
- Stem Cell Regulation by Death Ligands and Their Use in Cell Therapy
- Atypical Immune Functions of CD95/CD95L
- TLR3 is a Death Receptor Target in Cancer Therapy
- Fas/CD95, Lipid Rafts and Cancer
- Role of Sphingolipids in Death Receptor Signalling
- Post-Translational Modifications and Death Receptor Signalling
- System Modeling of Receptor-Induced Apoptosis.
